A research study to determine whether a therapeutic intervention - etanercept - will improve short-term outcomes associated with Stevens-Johnson Syndrome and toxic epidermal necrolysis (SJS/TEN) over normal standard of care.
ABOUT NATIENS
NATIENS is a clinical trial for adults 18 years and older who have been diagnosed with Stevens-Johnson Syndrome and toxic epidermal necrolysis (SJS/TEN). We will be enrolling a total of 150 participants at up to 22 medical institutions.
About SJS/TEN:
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are severe, life-threatening adverse drug reactions that affect 60,000 patients per year globally at an incidence of 5 cases per 1,000,000 in the United States. This is the only trial of this kind and treatment options are limited.
NATIENS Locations
Arizona
Valleywise Health Medical Center, Phoenix, AZ
California
University of California – Davis, Sacramento, CA
District of Columbia
MedStar Washington Hospital Center – Washington, DC
Florida
University of Florida – Gainesville, FL
University of Miami/Ryder Trauma Center – Miami, FL
Georgia
Emory at Grady Memorial Hospital – Atlanta, GA
Illinois
Loyola University/Chicago – Maywood, IL
Maryland
Johns Hopkins Bayview Medical Center – Baltimore, MD
Michigan
Wayne State University/Beaumont Medical Park - Dearborn, MI
Tennessee
University of Tennessee Health Science Center/Regional One Health – Memphis, TN
Vanderbilt University Medical Center – Nashville, TN
Texas
The University of Texas Medical Branch – Galveston, TX
University of Texas Southwestern Medical Center – Dallas, TX
Washington
University of Washington/Harborview Medical Center, Seattle, WA